# Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C

> **NCT03402165** · PHASE4 · UNKNOWN · sponsor: **Sherief Abd-Elsalam** · enrollment: 1200 (estimated)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir

## Key facts

- **NCT ID:** NCT03402165
- **Lead sponsor:** Sherief Abd-Elsalam
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-30
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2018-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03402165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03402165, "Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03402165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*